Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications

NCT01772004 is registered in ClinicalTrials.gov with EMD Serono Research & Development Institute, Inc. as lead sponsor.

NCT NCT01772004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01772004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2013
Completion date
December 16, 2019
Enrollment
1,756 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors